TIC Solutions, Inc.

NYSE · TIC
10.05−0.34−3.27%as of Oct 30, 2026

We are a leading provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. We provide mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings, and public infrastructure. Our services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. We operate primarily in North America and serve both private and public-sector clients. Our private-sector clients span industrial, infrastructure, construction, and commercial real estate end markets. Our public-sector clients include federal, state, and municipal agencies, public utilities, transportation authorities, and environmental regulators. Within industrial markets, our services address energy processing and refining, pipeline and midstream infrastructure, chemicals and industrial processing, manufacturing and industrial services, power generation and utilities, and companies in aerospace, automotive, renewable energy, pulp and paper, and mining. We provide these compliance-driven services and focus on the

From the 10-K filed Mar 12, 2026

CEO
Mr. Benjamin Heraud
Sector
Industrials
Industry
Specialty Business Services
Employees
11,084
Headquarters
Hollywood, FL
Fiscal year end
December
1 year−2.23 (−18.16%)
TIC−18.16%
$7.00$8.00$9.00$10$11$12
$10.05
20MVol
Oct '25Jan '26Mar '26Jun '26Aug '26Oct '26
FundalyzePowered by fundalyze.ai
6.3612.94

as of Oct 22, 2026 · today 10.05, 56% of the way from low to high

No dividends on record.

A company that pays none, or whose history has not arrived yet, shows nothing here.

Valuation

Market cap$2.20Bas of Oct 22, 2026
P/E-19.0×TTM · Q3 2025 – Q2 2026
P/S1.1×TTM · Q3 2025 – Q2 2026
P/B1.0×Q2 2026
Dividend yield—no dividends on record

Results, trailing twelve months

Revenue$2.05BTTM · Q3 2025 – Q2 2026
Net income-$115.98MTTM · Q3 2025 – Q2 2026
Diluted EPS-$0.53TTM · Q3 2025 – Q2 2026
Gross margin33.9%TTM · Q3 2025 – Q2 2026

Balance and cash

Enterprise value$3.45Bas of Oct 22, 2026
Long-term debt$1.59BQ2 2026
Free cash flow$22.23MTTM · Q3 2025 – Q2 2026
Stock-based comp.$38.41MTTM · Q3 2025 – Q2 2026

Shares and market

Shares outstanding218.99Mas of Oct 23, 2026
Average volume1.26Mshares a day, last 3 months
Beta1.874

Financial statements

Revenue +45.7% $1.05B → $1.53B, year ended Dec 31, 2025

Comps

Valuation, growth and margins against the closest competitors

Filings

10-K filed Mar 12, 2026 · 10-Q Aug 6, 2026

FilingFiled
10-Q for Quarter Ended June 2026Aug 6, 2026
10-Q for Quarter Ended March 2026May 6, 2026
10-K for Fiscal Year Ended December 2025Mar 12, 2026
10-Q for Quarter Ended September 2025Nov 12, 2025

Insiders

$502.63K sold open market, 12 months to Nov 18, 2025

InsiderTypeValue
Richard TongNov 18, 2025Sale$502.63K ↗

Funds (13F)

84.9% held by 224 managers · as of Sep 30, 2026

ManagerValueChange
VIKING GLOBAL INVESTORS LP$289.82M—
Permian Investment Partners, LP$172.40M−635.00K (−2.9%)
Gates Capital Management, Inc.$157.77M−2.35M (−10.7%)
Alyeska Investment Group, L.P.$150.51M−157.83K (−0.8%)
Progeny 3, Inc.$125.90M+239.88K (+1.6%)

Congress

4 trades 4 sales · 0 purchases · 1 members, 12 months

MemberTypeAmount
Richard BlumenthalAug 11, 2026Sale$250K–$500K
Richard BlumenthalAug 11, 2026Sale$500K–$1M
Richard BlumenthalAug 11, 2026Sale$15K–$50K
Richard BlumenthalAug 11, 2026Sale$100K–$250K

Short interest

22.99% of float · 16.91 days to cover · Oct 15, 2026

Short position, last two years · near a 2-year high

Source: FINRA

No headlines in the business press in the last 30 days.

Company data reported to the SEC on EDGAR (CIK 2032966).

Everything on TIC, in full

Every fiscal year and quarter as filed, the filing reader with highlights and AI summaries, insider and fund activity, congressional trades, short interest history, earnings calls, the full price history and every peer. A 7-day free trial, then a subscription.

Start your free trial